# Phase 1 ovarian cancer trials recruiting: 108 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 108 trials in phase 1 for ovarian cancer that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1 ovarian cancer trials: 108 rows for $5.40, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 2 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1/ovarian-neoplasms

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 108
- Recruiting or not yet: 108
- Read on: November 19, 2026

## Trials

The 25 newest of 108, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 17, 2026 | NCT07940881 | A Multicenter, Open-label, Phase 1/1b, Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SI-B037 in Solid Tumors | SystImmune Inc. | Phase 1 | Recruiting | Locally Advanced /Metastatic Solid Tumors, Locally Advanced / Metastatic Solid Tumors, First in Human, Metastatic Solid... | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07940881) |
| November 10, 2026 | NCT07928258 | A Study of LY4336619 in Adult Participants With Advanced Solid Tumors | Eli Lilly and Company | Phase 1 | Not yet recruiting | Endometrial Neoplasms, Ovarian Neoplasms, Neoplasms, Germ Cell and Embryonal, Carcinoma, Non-Small-Cell Lung, Stomach... | 370 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07928258) |
| November 6, 2026 | NCT07923214 | A Phase I Dose Escalation Study of CG-7321 Monotherapy or Combination Therapy in Advanced Solid Tumors | Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd. | Phase 1 | Recruiting | Advanced Solid Tumors, Breast Cancer, Ovarian Cancer, Gastric Cancer, Other Solid Tumors | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07923214) |
| October 29, 2026 | NCT07905677 | Phase 1 Study of VT-101 in Advanced Ovarian Cancer | Sponsor not shown (see the record) | Phase 1 | Recruiting | Epithelial Ovarian Cancer, Ovarian Cancer | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07905677) |
| October 26, 2026 | NCT07894874 | A Study to Evaluate YF550 in Participants With Locally Advanced or Metastatic Solid Tumors. | InventisBio Yiqi Beijing Limited | Phase 1 | Not yet recruiting | Solid Tumor (Phase I), Ovarian Cancer, NSCLC (Advanced Non-small Cell Lung Cancer), TNBC - Triple-Negative Breast Cancer | 204 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07894874) |
| October 13, 2026 | NCT07870278 | A Clinical Trial of MK-6255 to Treat Endometrial and Ovarian Cancer (MK-6255-001) | Merck Sharp & Dohme LLC | Phase 1 | Not yet recruiting | Ovarian Neoplasms, Endometrial Neoplasms | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07870278) |
| September 11, 2026 | NCT07815951 | Safety and Diagnostic Performance of 111In-TJD-31 SPECT Imaging in Patients With Solid Tumors | Sponsor not shown (see the record) | Phase 1 | Not yet recruiting | Solid Tumors, Carcinoma, Ovarian Neoplasms, Endometrial Neoplasms Malignant, Testicular Neoplasms, Lung Neoplasms... | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07815951) |
| September 10, 2026 | NCT07814248 | A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a... | TwoStep Therapeutics, Inc. | Phase 1 | Recruiting | NSCLC (Non-small Cell Lung Cancer), HNSCC, Endometrial, Ovarian Cancer, Esophageal Cancer, Head & Neck Cancer, Gastric... | 74 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07814248) |
| September 8, 2026 | NCT07807956 | A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With... | AbbVie | Phase 1 | Recruiting | Advanced Solid Tumors, Non-Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Gastric Cancer... | 130 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07807956) |
| August 10, 2026 | NCT07755436 | Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic... | ArriVent BioPharma, Inc. | Phase 1 | Recruiting | Ovarian Cancer, Endometrial Cancer, Platinum-resistant Ovarian Cancer (PROC), Metastatic Ovarian Cancer, Metastatic... | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07755436) |
| July 29, 2026 | NCT07733505 | Normethermic Intraperitoneal Chemotherapy - a Novel Concept for Local Treatment of the Elderly and Fragile Women With Advanced Ovarian... | Odense University Hospital | Phase 1 | Recruiting | Ovarian Cancer | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07733505) |
| July 23, 2026 | NCT07724106 | A Single-Arm, Open-Label, Prospective Study Evaluating the Safety, Tolerability, and Immunogenicity of the NeoOVSV Vaccine in Patients With... | West China Hospital | Phase 1 | Recruiting | Ovarian Cancer, mRNA Vaccine | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07724106) |
| July 20, 2026 | NCT07715747 | A Study to Evaluate the Safety,Pharmacokinetics,Pharmacodynamics,and Efficacy of TJ037130 in Adult Participants With Advanced Solid Tumors | TJ Biopharma Co., Ltd. | Phase 1 | Recruiting | Solid Tumor, Metastatic Ovary Cancer, Metastatic Gastric Cancer, Metastatic Endometrial Carcinoma | 128 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07715747) |
| July 8, 2026 | NCT07690189 | Study of NTB-928 in R/R OC | TeneoSeven, Inc. | Phase 1 | Recruiting | Relapsed/Refractory Ovarian Carcinoma | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07690189) |
| June 30, 2026 | NCT07676890 | A Single-Arm, Open-Label, Prospective Study Evaluating the Safety, Tolerability, and Immunogenicity of the NeoOVIV Vaccine in Patients With... | West China Hospital | Phase 1 | Recruiting | Ovarian Cancer, mRNA Vaccine | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07676890) |
| June 29, 2026 | NCT07674615 | IMMU-132 in TROP-2 Overexpressed Advanced and Relapsed Ovarian Cancer | Shanghai Gynecologic Oncology Group | Phase 1 | Not yet recruiting | Epithelial Ovarian Cancer, Fallopian Tube Cancers, Primary, Primary Peritoneal Carcinoma | 19 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07674615) |
| June 24, 2026 | NCT07665515 | Study of CryptiVax-1001 in Maintenance Setting for Advanced Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Epitopea Ltd | Phase 1 | Recruiting | Ovarian Cancer, HGSOC, HGS Ovarian, Fallopian Tube or Primary Peritoneal Cancer | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07665515) |
| June 24, 2026 | NCT07664735 | A Study to Evaluate OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer. | Outpace Bio, Inc. | Phase 1 | Recruiting | Endometrial Cancer Recurrent, Endometrial Cancer, Advanced Endometrial Cancer, Ovarian Cancer, Ovarian Cancer... | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07664735) |
| June 3, 2026 | NCT07623369 | A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors | Huahui Health | Phase 1 | Recruiting | Solid Tumor, Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Colorectal Cancer, Head and Neck Squamous Cell... | 299 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07623369) |
| May 29, 2026 | NCT07613723 | A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid Malignancies | Sponsor not shown (see the record) | Phase 1 | Recruiting | Ovarian Cancer, Squamous Non-Small Cell Lung Cancer (NSCLC), Synovial Sarcomas, Head and Neck Cancer | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07613723) |
| May 18, 2026 | NCT07593092 | Phase 1, Safety and Tolerability Study of XmAb541 and XmAb808 in Advanced Solid Tumors | Xencor, Inc. | Phase 1 | Recruiting | Ovarian Cancer | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07593092) |
| April 15, 2026 | NCT07532148 | Study of CKD-215 and D215 in Adults With BRCA-mutated Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Chong Kun Dang Pharmaceutical | Phase 1 | Not yet recruiting | Ovarian Cancer | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07532148) |
| April 13, 2026 | NCT07524322 | Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors | Regor Pharmaceuticals Inc. | Phase 1 | Recruiting | Breast Cancer, Ovarian Cancer, Endometrial Cancer, PIK3CA Mutation, HER2- Negative Breast Cancer, Advanced Breast... | 63 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07524322) |
| April 8, 2026 | NCT07517198 | Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | Phase 1 | Recruiting | Solid Tumor, Small Cell Lung Cancer (SCLC), High Grade Neuroendocrine Cancer, Small Cell Carcinomas of Non-lung Origin... | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07517198) |
| March 24, 2026 | NCT07489287 | GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer | Roswell Park Cancer Institute | Phase 1 | Recruiting | Platinum-resistant Ovarian Cancer | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07489287) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| M.D. Anderson Cancer Center | 6 |
| [Eli Lilly and Company](https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company) | 4 |
| Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd | 3 |
| SystImmune Inc. | 3 |
| West China Hospital | 2 |
| Shanghai Gynecologic Oncology Group | 2 |
| [AbbVie](https://specstream.ai/data/clinical-trials/company/abbvie) | 2 |
| [Xencor, Inc.](https://specstream.ai/data/clinical-trials/company/xencor-inc) | 2 |
| National Cancer Institute (NCI) | 2 |
| City of Hope Medical Center | 2 |
| Whitehawk Therapeutics, Inc. | 2 |
| [Jiangsu Hansoh Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/jiangsu-hansoh-pharmaceutical-co-ltd) | 2 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 2 |
| MOMA Therapeutics | 1 |
| Degron Therapeutics Co. | 1 |
| Dana-Farber Cancer Institute | 1 |
| Conjupro Biotherapeutics, Inc. | 1 |
| ImmVirx Pty Ltd | 1 |
| PhotonPharma, Inc. | 1 |
| GONGCHU Biotechnology Co., Ltd | 1 |
| InventisBio Yiqi Beijing Limited | 1 |
| Hospices Civils de Lyon | 1 |
| TwoStep Therapeutics, Inc. | 1 |
| [TJ Biopharma Co., Ltd.](https://specstream.ai/data/clinical-trials/company/tj-biopharma-co-ltd) | 1 |
| Outpace Bio, Inc. | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 68 |
| China | 24 |
| Spain | 13 |
| Australia | 11 |
| United Kingdom | 10 |
| France | 9 |
| Japan | 8 |
| South Korea | 7 |
| Portugal | 2 |
| Taiwan | 2 |
| Belgium | 2 |
| Denmark | 2 |
| Germany | 2 |
| Italy | 2 |
| Israel | 1 |
| Netherlands | 1 |
| Switzerland | 1 |
| Georgia | 1 |
| Ireland | 1 |
| Canada | 1 |
| Lebanon | 1 |
| Poland | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Real estate law firms in the United States](https://specstream.ai/data/businesses/real-estate-law-firms/united-states)
- [Land surveyors in the United States](https://specstream.ai/data/businesses/land-surveyors/united-states)
- [Educational supply stores in the United States](https://specstream.ai/data/businesses/educational-supply-stores/united-states)
- [B2B international trade companies in the United States](https://specstream.ai/data/businesses/b2b-international-trade-companies/united-states)
- [South African restaurants in the United States](https://specstream.ai/data/businesses/south-african-restaurants/united-states)
- [Metal plating companies in the United States](https://specstream.ai/data/businesses/metal-plating-companies/united-states)
